Baker Brothers Advisors - TCR2 THERAPEUTICS INC ownership

TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 122 filers reported holding TCR2 THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 2.23 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of TCR2 THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$1,129,596
+50.2%
753,0640.0%0.01%
+20.0%
Q4 2022$752,160
-44.5%
753,0640.0%0.01%
-44.4%
Q3 2022$1,356,000
-37.9%
753,0640.0%0.01%
-25.0%
Q2 2022$2,184,000
+5.1%
753,0640.0%0.01%0.0%
Q1 2022$2,078,000
-40.8%
753,0640.0%0.01%
-29.4%
Q4 2021$3,509,000
+133.6%
753,064
+326.8%
0.02%
+142.9%
Q3 2021$1,502,000
-48.1%
176,4610.0%0.01%
-46.2%
Q2 2021$2,896,000
-25.7%
176,4610.0%0.01%
-23.5%
Q1 2021$3,896,000
+13.6%
176,461
+59.1%
0.02%
+30.8%
Q4 2020$3,430,000
+37.8%
110,888
-9.5%
0.01%
+30.0%
Q3 2020$2,490,000122,5320.01%
Other shareholders
TCR2 THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
MPM BioImpact LLC 6,741,964$208,528,00018.01%
MPM ASSET MANAGEMENT LLC 4,050,865$125,293,00017.73%
Consonance Capital Management LP 584,885$71,268,0006.66%
SILVERARC CAPITAL MANAGEMENT, LLC 136,000$4,206,0002.44%
Redmile Group, LLC 2,832,888$87,621,0001.06%
Altium Capital Management LP 73,991$2,289,0000.86%
PFM Health Sciences, LP 775,794$23,995,0000.84%
Soleus Capital Management, L.P. 199,867$6,182,0000.82%
MOODY ALDRICH PARTNERS LLC 123,639$3,824,0000.62%
Sofinnova Investments, Inc. 333,707$10,322,0000.61%
View complete list of TCR2 THERAPEUTICS INC shareholders